Navigation Links
New Moffitt Cancer Center patent promises to accelerate cancer trials
Date:2/14/2012

TAMPA, Fla. A new patent has been issued to Moffitt Cancer Center for a computerized system that efficiently selects the right patient for the right clinical trial. The newly patented system matches the registered patient's own molecular profile warehoused in a database of thousands of patient-donated biological tissue or tumor samples to the molecular design of the drug aimed at targeting their disease at the molecular level, and does it quickly. The system promises to accelerate clinical trials and help shorten the time that it takes to get critically needed new drugs into the market.

Getting new drugs to market to fight cancer and other serious diseases requires, on average, 15 years. The drug development process is long and complex, but the three-phase clinical trials process estimated to take up to half of those 15 years is often the bottleneck in getting innovative drugs to the patients who need them.

Clinical trials, increasingly becoming more expensive, are also multifaceted. While patients may qualify for a clinical trial based on their age or stage of disease, they may not be, over the long term of the trial, the best candidates to test a drug. Adverse events, changes in a patient's health status and the potential for a drug not being effective for them slow the process. Although patients may have met the trial protocol's criteria, the drug may not be right for them because their molecular profile is not a good match for the chemical and molecular properties of the drug.

Because the concept of personalized medicine is selecting the right drug for the right patient, innovations have been needed to bring personalized medicine to reality. Personalizing the selection process for clinical trials is a vital step.

With the development of new and better ways to examine and understand a tumor's molecular profile, matching the right patient to the right clinical trial becomes increasingly important. But handling the massive data evaluation necessary to accomplish this has been a stumbling block.

The newly patented computer system, Patent Number US 8,095,389 B2, or "Computer Systems and Methods for Selecting Patients for Clinical Trials," is designed to surmount that problem.

The newly patented computer system is designed to:

  • Select patients to clinical trials matching an individual's/drug's molecular profile
  • Match patients to clinical trials by a patient's disease/diagnosis
  • Match patients to clinical trials by their symptoms
  • Match patients to clinical trials by their demographic information and family history
  • Track a clinical trial participant's disease progression compared to drug efficacy

The newly patented computer system and associated products, such as operating system, software, interfaces and data retrieval system, improve clinical trial selection efficacy by making the patient selection process less random and more selective. The technology has the potential to refine clinical trials by eliminating bottlenecks, overhauling the selection process and shortening the timeline, ultimately bringing new drugs to market more efficiently.


'/>"/>
Contact: Michelle Foley
Michelle.Foley@moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida
2. Fibroblasts contribute to melanoma tumor growth, say Moffitt Cancer Center researchers
3. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
4. Moffitt researchers will be strong participants in American Society of Hematology meeting
5. Moffitt Cancer Center researchers find MK1775 active against sarcomas
6. Moffitt Cancer Center researchers find men less willing to be screened for cancer
7. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
8. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
9. Moffitt Cancer Center researchers find more clues to causes of breast cancer
10. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
11. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the ... CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. ... across the United States. , “There are currently no approved drugs that address ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... On Wednesday, February 22, 2017, US ... of nine sectors finished the trading sessions in green, four ... Major US indices were also mixed at the close of ... slightly down by 0.09%; the Dow Jones Industrial Average edged ... closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks ...
(Date:2/23/2017)... , February 23, 2017 Tillotts ... the Berlin office was opened ... Kritikos . The portfolio includes Entocort ® for ... the treatment of ulcerative colitis, and VistaPrep ® ... the Swiss specialty pharmaceutical company focused on the treatment ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
Breaking Medicine Technology: